Despite all these considerations, the KEAP1 silencing studies support the hypothesis that KEAP1 acts in lung carcinoids by modulating the levels of NRF2 and the NRF2-detoxification enzymes TXNRD1 and NQO1. Here, NQO1 is linked to lung carcinoid tumor.